BTC Capital Management Inc. Increases Position in AbbVie Inc. $ABBV

BTC Capital Management Inc. grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.3% in the first quarter, Holdings Channel reports. The firm owned 74,317 shares of the company’s stock after acquiring an additional 2,401 shares during the period. AbbVie accounts for approximately 1.1% of BTC Capital Management Inc.’s holdings, making the stock its 23rd largest position. BTC Capital Management Inc.’s holdings in AbbVie were worth $16,160,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of AbbVie in the fourth quarter valued at approximately $5,865,055,000. Wellington Management Group LLP increased its holdings in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Capital World Investors raised its position in AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares in the last quarter. Cardano Risk Management B.V. raised its position in AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after buying an additional 4,190,487 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $243.65 on Friday. The stock’s 50-day simple moving average is $214.30 and its 200-day simple moving average is $218.96. The firm has a market capitalization of $430.47 billion, a PE ratio of 120.02, a P/E/G ratio of 0.72 and a beta of 0.32. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.46 earnings per share. Sell-side analysts forecast that AbbVie Inc. will post 14.29 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s dividend payout ratio is currently 340.89%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ABBV shares. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Morgan Stanley increased their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, Canaccord Genuity Group lifted their price target on AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord raised its price target on AbbVie to $273 from $265 and reiterated a Buy rating, saying the Apogee acquisition improves AbbVie’s long-term growth outlook. Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
• Positive Sentiment: AbbVie’s Apogee deal is being viewed as a potentially accretive immunology bet, with articles highlighting the chance to add a prospective blockbuster asset and boost future revenue growth. AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie also expanded its pipeline by launching a new Phase 1 safety study for bretisilocin, adding another early-stage growth opportunity. AbbVie Expands Pipeline With New Bretisilocin Phase 1 Safety Study
• Positive Sentiment: AbbVie received EU approval for Skyrizi in pediatric plaque psoriasis, expanding the drug’s addressable market and supporting its immunology franchise. AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
• Neutral Sentiment: Several lifestyle and brand-related items highlighted Allergan Aesthetics and BOTOX® Cosmetic initiatives, including Formula Wellness earning Top 50 status and the Confidence Collective entrepreneur program. These reinforce AbbVie’s consumer aesthetics presence, but are unlikely to move the stock materially on their own. Formula Wellness Earns Top 50 Status for 2026 from Allergan Aesthetics

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.